JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 25, 2005; DOI: 10.1124/jpet.105.090167


0022-3565/05/3153-1172-1180$20.00
JPET 315:1172-1180, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.090167v1
315/3/1172    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porath, D.
Right arrow Articles by Schwager, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porath, D.
Right arrow Articles by Schwager, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Antioxidants

INFLAMMATION AND IMMUNOPHARMACOLOGY

Epigallocatechin-3-gallate Impairs Chemokine Production in Human Colon Epithelial Cell Lines

Debora Porath, Christoph Riegger, Juergen Drewe, and Joseph Schwager

DSM Nutritional Products Ltd., Research and Development, Human Nutrition and Health, Kaiseraugst, Switzerland (D.P., C.R., J.S.); and Institute of Clinic Pharmacology and Toxicology, Department of Pharmacy, University of Basel, Basel, Switzerland (J.D.)

A major component in green tea, epigallocatechin-3-gallate (EGCG), is reported to interfere with different steps of a number of inflammatory pathways. After oral administration, EGCG is retained in the gastrointestinal tract, where it is thought to exert preventive functions against inflammatory bowel disease and colon cancer. In this study, the human colon adenocarcinoma cell lines HT29 and T84 were used to investigate the effect of EGCG on intestinal inflammation. HT29 and T84 cells were stimulated with tumor necrosis factor (TNF)-{alpha} to induce the inflammatory condition and to trigger the inflammatory cascade in vitro and treated with EGCG to study its effect on inflammatory processes. The secretion of the chemokines interleukin (IL)-8, macrophage inflammatory protein (MIP)-3{alpha}, and prostaglandin E2 (PGE2) was determined by enzyme-linked immunosorbent assay. The gene expression level was measured by quantitative real-time polymerase chain reaction. Treatment of TNF-{alpha}-stimulated HT29 cells with EGCG dose-dependently inhibited the synthesis of IL-8, MIP-3{alpha}, and PGE2. Treatment with EGCG also inhibited the production of IL-8 and MIP-3{alpha} in TNF-{alpha}-stimulated T84 cells. Gene expression analysis in both HT29 and T84 cells revealed that EGCG down-regulates genes involved in inflammatory pathways. This study shows that EGCG acts broadly on the production of chemokines and PGE2 in the chemokine and eicosanoid pathways of colon epithelial cells. Therefore, EGCG might prove useful for the prevention and/or attenuation of colonic disorders.


Received May 30, 2005; accepted August 16, 2005.

Address correspondence to: Joseph Schwager, DSM Nutritional Products Ltd., Building 205/209, P.O. Box 3255, Wurmisweg 576, CH-4303 Kaiseraugst, Switzerland. E-mail: joseph.schwager{at}dsm.com




This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. Lewis, J. Caldwell, V. Phan, D. Prescott, A. Nazli, A. Wang, J. D. Soderholm, M. H. Perdue, P. M. Sherman, and D. M. McKay
Decreased epithelial barrier function evoked by exposure to metabolic stress and nonpathogenic E. coli is enhanced by TNF-{alpha}
Am J Physiol Gastrointest Liver Physiol, March 1, 2008; 294(3): G669 - G678.
[Abstract] [Full Text] [PDF]


Home page
Nutr Clin PractHome page
J. O. Clarke and G. E. Mullin
A Review of Complementary and Alternative Approaches to Immunomodulation
Nutr Clin Pract, February 1, 2008; 23(1): 49 - 62.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Coll. Nutr.Home page
C. A. Rowe, M. P. Nantz, J. F. Bukowski, and S. S. Percival
Specific Formulation of Camellia sinensis Prevents Cold and Flu Symptoms and Enhances {gamma}{delta} T Cell Function: A Randomized, Double-Blind, Placebo-Controlled Study
J. Am. Coll. Nutr., October 1, 2007; 26(5): 445 - 452.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. Yang, X.-O. Shu, H. Li, W.-H. Chow, B.-T. Ji, X. Zhang, Y.-T. Gao, and W. Zheng
Prospective Cohort Study of Green Tea Consumption and Colorectal Cancer Risk in Women
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1219 - 1223.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.